35.78
price down icon5.14%   -1.94
after-market アフターアワーズ: 35.08 -0.70 -1.96%
loading
前日終値:
$37.72
開ける:
$38.05
24時間の取引高:
783.88K
Relative Volume:
0.56
時価総額:
$1.22B
収益:
$55.63M
当期純損益:
$-158.10M
株価収益率:
-4.2493
EPS:
-8.4202
ネットキャッシュフロー:
$-203.94M
1週間 パフォーマンス:
-13.09%
1か月 パフォーマンス:
-46.90%
6か月 パフォーマンス:
-57.40%
1年 パフォーマンス:
-34.90%
1日の値動き範囲:
Value
$35.61
$38.05
1週間の範囲:
Value
$35.61
$40.98
52週間の値動き範囲:
Value
$33.40
$109.00

Nektar Therapeutics Stock (NKTR) Company Profile

Name
名前
Nektar Therapeutics
Name
セクター
Healthcare (1052)
Name
電話
(415) 482-5300
Name
住所
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Name
職員
63
Name
Twitter
@nektarnews
Name
次回の収益日
2026-11-05
Name
最新のSEC提出書
Name
NKTR's Discussions on Twitter

Compare NKTR vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
NKTR icon
NKTR
Nektar Therapeutics
35.78 1.22B 55.63M -158.10M -203.94M -8.4202
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
499.74 126.66B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
218.01 87.04B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
790.74 81.41B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
819.14 51.51B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
369.06 41.75B 5.76B 514.49M 1.10B 4.4813

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-10-12 開始されました Leerink Partners Outperform
2026-10-12 開始されました UBS Neutral
2026-10-09 開始されました Raymond James Mkt Perform
2026-08-21 再開されました JP Morgan Neutral
2026-07-22 開始されました Canaccord Genuity Buy
2026-03-24 開始されました Wedbush Neutral
2026-03-17 開始されました TD Cowen Buy
2026-02-10 アップグレード William Blair Mkt Perform → Outperform
2025-11-26 開始されました Citigroup Buy
2025-06-24 繰り返されました BTIG Research Buy
2025-06-24 繰り返されました H.C. Wainwright Buy
2025-04-11 アップグレード Jefferies Hold → Buy
2025-03-14 アップグレード Oppenheimer Perform → Outperform
2025-01-08 開始されました B. Riley Securities Buy
2024-12-10 開始されました H.C. Wainwright Buy
2024-11-04 開始されました Piper Sandler Overweight
2024-09-30 再開されました BTIG Research Buy
2024-06-28 開始されました Rodman & Renshaw Buy
2023-11-20 再開されました JP Morgan Underweight
2023-11-09 アップグレード TD Cowen Market Perform → Outperform
2023-05-10 アップグレード Jefferies Underperform → Hold
2023-02-24 ダウングレード Jefferies Hold → Underperform
2022-08-08 ダウングレード JP Morgan Neutral → Underweight
2022-05-31 再開されました Jefferies Hold
2022-04-18 ダウングレード Goldman Neutral → Sell
2022-03-15 ダウングレード Cowen Outperform → Market Perform
2022-03-15 ダウングレード Mizuho Buy → Neutral
2022-03-14 ダウングレード BTIG Research Buy → Neutral
2022-03-14 ダウングレード BofA Securities Neutral → Underperform
2022-03-14 ダウングレード Stifel Buy → Hold
2022-03-14 ダウングレード William Blair Outperform → Mkt Perform
2022-03-09 アップグレード Oppenheimer Perform → Outperform
2021-11-08 アップグレード The Benchmark Company Hold → Buy
2021-09-10 開始されました BofA Securities Neutral
2021-06-28 アップグレード Stifel Hold → Buy
2021-05-18 再開されました Goldman Neutral
2021-02-22 ダウングレード The Benchmark Company Buy → Hold
2021-01-06 開始されました Stifel Hold
2020-09-14 開始されました JP Morgan Neutral
2020-06-10 ダウングレード CFRA Hold → Sell
2020-05-12 繰り返されました H.C. Wainwright Neutral
2020-04-22 開始されました The Benchmark Company Buy
2020-03-30 アップグレード Goldman Sell → Neutral
2020-03-04 開始されました Barclays Overweight
2020-02-03 アップグレード Mizuho Neutral → Buy
2019-10-24 開始されました Oppenheimer Perform
2019-10-08 ダウングレード Goldman Buy → Sell
2019-08-09 ダウングレード JP Morgan Overweight → Neutral
2019-08-09 ダウングレード Jefferies Buy → Hold
2019-08-09 ダウングレード Mizuho Buy → Neutral
2019-03-15 開始されました SVB Leerink Mkt Perform
2018-12-13 開始されました Goldman Buy
2018-06-11 ダウングレード H.C. Wainwright Buy → Neutral
2018-06-04 繰り返されました H.C. Wainwright Buy
2018-04-20 開始されました Seaport Global Securities Buy
2018-04-13 再開されました Piper Jaffray Overweight
2018-04-06 繰り返されました Mizuho Buy
2018-04-02 再開されました H.C. Wainwright Buy
すべてを表示

Nektar Therapeutics (NKTR) 最新ニュース

pulisher
Oct 15, 2026

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry? - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 15, 2026

Nektar Therapeutics (NKTR) Could Be 72% Undervalued On New Rezpegaldesleukin Data - Simply Wall Street

Oct 15, 2026
pulisher
Oct 13, 2026

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC) - The Globe and Mail

Oct 13, 2026
pulisher
Oct 13, 2026

Analysts Offer Insights on Healthcare Companies: Nektar Therapeutics (NKTR), Roche Holding AG (OtherRHHVF) and Henry Schein (HSIC) - The Globe and Mail

Oct 13, 2026
pulisher
Oct 12, 2026

Nektar Therapeutics Initiated at Neutral by UBS - Moomoo

Oct 12, 2026
pulisher
Oct 12, 2026

UBS Initiates Nektar Therapeutics(NKTR.US) With Hold Rating, Announces Target Price $53 - Moomoo

Oct 12, 2026
pulisher
Oct 12, 2026

Leerink Highlights Nektar Therapeutics (NKTR) as Top Emerging Te - GuruFocus

Oct 12, 2026
pulisher
Oct 12, 2026

Nektar, Protagonist, Shattuck are Leerink top picks in emerging immunology - Seeking Alpha

Oct 12, 2026
pulisher
Oct 12, 2026

Nektar Therapeutics Price Target Announced at $53.00/Share by UBS - Moomoo

Oct 12, 2026
pulisher
Oct 12, 2026

Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target - marketscreener.com

Oct 12, 2026
pulisher
Oct 12, 2026

Leerink Partners Initiates Nektar Therapeutics at Outperform, $130 Price Target - Yahoo Finance

Oct 12, 2026
pulisher
Oct 12, 2026

UBS initiates Nektar Therapeutics stock at Neutral on catalyst timing By Investing.com - Investing.com Nigeria

Oct 12, 2026
pulisher
Oct 09, 2026

Raymond James Initiates Nektar Therapeutics at Market Perform - Yahoo Finance

Oct 09, 2026
pulisher
Oct 09, 2026

Lawsuit Win Could Be A Game Changer For Nektar Therapeutics (NKTR) - Simply Wall Street

Oct 09, 2026
pulisher
Oct 07, 2026

Nektar Therapeutics stock faces a cash runway into 2028 - AD HOC NEWS

Oct 07, 2026
pulisher
Oct 07, 2026

Is Nektar Therapeutics (NKTR) Cheap As Rezpegaldesleukin Data Supports Phase 3 Plans? - Simply Wall Street

Oct 07, 2026
pulisher
Oct 07, 2026

Nektar Therapeutics (NKTR) stock price, news, quote and history - Yahoo Finance Singapore

Oct 07, 2026
pulisher
Oct 07, 2026

Nektar Therapeutics (NKTR) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 07, 2026
pulisher
Oct 07, 2026

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang - Yahoo Finance

Oct 07, 2026
pulisher
Oct 06, 2026

Nektar's Phase 2b Data Shows Durable Eczema, Alopecia Response - Streetwise Reports

Oct 06, 2026
pulisher
Oct 05, 2026

Nektar Therapeutics stock analysis: oversold technicals meet binary clinical risk - Investing.com

Oct 05, 2026
pulisher
Oct 05, 2026

Citi Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $151 - Moomoo

Oct 05, 2026
pulisher
Oct 03, 2026

Nektar Therapeutics (NKTR) Shareholder/Analyst CallSlideshow (NASDAQ:NKTR) 2026-10-03 - Seeking Alpha

Oct 03, 2026
pulisher
Oct 03, 2026

Nektar Therapeutics Company Profile & Introduction - Moomoo

Oct 03, 2026
pulisher
Oct 02, 2026

Two Seas Capital LP Adds Nektar Therapeutics (NKTR) -- Shares Look 766% Overvalued on GF Value - GuruFocus

Oct 02, 2026
pulisher
Oct 02, 2026

Nektar Therapeutics Stock Price Forecast. Should You Buy NKTR? - StockInvest.us

Oct 02, 2026
pulisher
Oct 02, 2026

Nektar Therapeutics: Downgrade To Hold On REZPEG Market Outlook Setback And More (NKTR) - Seeking Alpha

Oct 02, 2026
pulisher
Oct 02, 2026

HC Wainwright & Co. reiterates Buy rating on Nektar Therapeutics, $185 price target - TradingView

Oct 02, 2026
pulisher
Oct 02, 2026

Nektar Therapeutics (NasdaqCM:NKTR) Stock Forecast & Analyst Predictions - Simply Wall Street

Oct 02, 2026
pulisher
Oct 02, 2026

Nektar Discloses Phase 2b Data for REZPEG in Severe Alopecia Areata - The Clinical Trial Vanguard

Oct 02, 2026
pulisher
Oct 01, 2026

Jefferies sets $150 target for Nektar Therapeutics amid promising alopecia drug data despite stock drop. - Pluang

Oct 01, 2026
pulisher
Oct 01, 2026

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge - Yahoo Finance

Oct 01, 2026
pulisher
Oct 01, 2026

Jefferies Analyst Defends Nektar Therapeutics (NKTR) Amid 21% St - GuruFocus

Oct 01, 2026
pulisher
Oct 01, 2026

Why This Biotech Took A 21% Hit On Promising Alopecia Results - Investor's Business Daily

Oct 01, 2026
pulisher
Oct 01, 2026

Nektar Therapeutics (NKTR) Shares Drop After Rezpegaldesleukin T - GuruFocus

Oct 01, 2026
pulisher
Oct 01, 2026

William Blair Reaffirms Outperform on Nektar Therapeutics (NKTR) Amid Rezpeg Data Advances - GuruFocus

Oct 01, 2026
pulisher
Oct 01, 2026

Nektar Therapeutics (NKTR) Stock Forecasts - Yahoo! Finance Canada

Oct 01, 2026
pulisher
Oct 01, 2026

This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking? - Barron's

Oct 01, 2026
pulisher
Oct 01, 2026

Nektar Therapeutics Down Nearly 21%, on Pace for Largest Percent Decrease Since February 2023 -- Data Talk - Moomoo

Oct 01, 2026
pulisher
Oct 01, 2026

Nektar REZPEG Data Show Durable Hair Regrowth, Set Up Phase III Alopecia Trial - Yahoo Finance

Oct 01, 2026
pulisher
Oct 01, 2026

New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 - PR Newswire

Oct 01, 2026
pulisher
Oct 01, 2026

Nektar Therapeutics Rezpegaldesleukin Demonstrates Durability And Deepening Of Response Through One Year Of Treatment - TradingView

Oct 01, 2026
pulisher
Oct 01, 2026

Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Nektar Therapeutics (NKTR) and Stryker (SYK) - The Globe and Mail

Oct 01, 2026
pulisher
Oct 01, 2026

/UPDATE -- Nektar Therapeutics/ - Yahoo Finance

Oct 01, 2026
pulisher
Sep 30, 2026

Asset turnover of Nektar Therapeutics – HAN:ITH0 - TradingView

Sep 30, 2026
pulisher
Sep 30, 2026

How Investors May Respond To Nektar Therapeutics (NKTR) New Phase 2b Data Presentations - webull.com

Sep 30, 2026
pulisher
Sep 30, 2026

How New Rezpegaldesleukin Durability and Mechanistic Data Could Impact Nektar Therapeutics (NKTR) Investors - Yahoo Finance

Sep 30, 2026
pulisher
Sep 29, 2026

What Could Nektar Therapeutics (NKTR) New Rezpegaldesleukin Data Mean For Its Case? - Yahoo Finance

Sep 29, 2026
pulisher
Sep 29, 2026

How Investors May Respond To Nektar Therapeutics (NKTR) New Phase 2b Data Presentations - Simply Wall Street

Sep 29, 2026

Nektar Therapeutics (NKTR) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Nektar Therapeutics (NKTR) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Zalevsky Jonathan
Officer
Aug 18 '26
Proposed Sale
71.98
186
13,388
0
ROBIN HOWARD W
Officer
Aug 18 '26
Proposed Sale
71.98
418
30,087
0
ROBIN HOWARD W
President & CEO
Aug 18 '26
Sale
71.98
418
30,088
54,627
Zalevsky Jonathan
Chief R&D Officer
Jun 30 '26
Sale
70.00
5,681
397,670
9,756
JONATHAN ZALEVSKY
Officer
Jun 30 '26
Proposed Sale
65.39
5,681
371,481
0
ROBIN HOWARD W
President & CEO
Jun 17 '26
Sale
61.19
10,000
611,880
55,045
ROBIN HOWARD W
Officer
Jun 17 '26
Proposed Sale
60.27
10,000
602,700
0
ROBIN HOWARD W
Officer
Jun 16 '26
Proposed Sale
60.96
10,000
609,600
0
ROBIN HOWARD W
President & CEO
Jun 16 '26
Sale
60.32
10,000
603,176
65,045
Zalevsky Jonathan
Chief R&D Officer
Jun 15 '26
Sale
60.71
5,538
336,212
15,437
$13.03
price down icon 6.12%
$34.46
price down icon 4.38%
$18.15
price down icon 3.51%
$36.74
price up icon 0.14%
$3.62
price down icon 2.95%
$16.20
price down icon 13.78%
大文字化:     |  ボリューム (24 時間):